Emergency physician Iyesatta Massaquoi Emeli argues for a fundamental redesign of how patients access healthcare, suggesting that the traditional waiting room model is becoming obsolete. This shift could improve patient experience and streamline care delivery.
The FDA has failed to meet its own deadline to prohibit the use of electrical shock devices on individuals with intellectual disabilities, prompting strong reactions from disability rights advocates.
Biotech is driving scientific breakthroughs that were once unimaginable. However, Jeremy Levin, a veteran executive in the industry, warns that while the future of biotech looks promising, the institutions supporting these innovations—ranging from regulators and investors to the broader public—face significant challenges that could jeopardize America's leadership in the field.
Democratic lawmakers in Congress are renewing efforts to terminate the Medicare pilot program that employs artificial intelligence to approve or deny medical services.
At STAT's Breakthrough Summit West, Jorie Krause's parents shared their story of how artificial intelligence played a crucial role in diagnosing and treating their daughter's ultra-rare condition. They described the moment they saw the impact of AI as almost like flipping a light switch, bringing hope where there was little before.
Steve D. Klein emphasizes that while AI has the potential to advance medical decision-making, direct and unregulated exchanges between AI systems and patients, particularly in addiction treatment, carry significant risks.
Within the gene therapy community, frustration mounts as Capsida has yet to disclose which brain receptor was involved when the adverse event occurred, delaying progress in understanding the incident.
People are increasingly turning to AI as a way to ease the mental effort required for decision-making and problem-solving. While this reliance can be helpful, for some individuals it risks becoming an unhealthy dependence that diminishes their ability to think critically on their own.
Relying on a patchwork of state regulations for clinical AI won't ensure safe and consistent healthcare. Instead, a unified national framework is needed to license AI medical applications, ensuring they meet rigorous standards for patient safety and effectiveness. This approach balances innovation with accountability, paving the way for responsible deployment of AI in medicine.
An overview of critical developments in biotech, including a lawsuit surrounding a Duchenne muscular dystrophy therapy and the White House complications faced by FDA Commissioner Marty Makary, featured in The Readout.